Director, Drug Information Service, Robert Wood Johnson University Hospital, New Brunswick, NJ, and Clinical Associate Professor, Ernest Mario School of Pharmacy, Rutgers, The State University of ...
A systematic review and meta-analysis identified factors contributing to post-kidney transplant anemia and the effect of erythropoietin-stimulating agents (ESAs).
Merck of Whitehouse Station, New Jersey, has halted development of its lead biogeneric product, MK-2578, a PEGylated erythropoietin-stimulating agent for treating anemia. The decision, announced ...
Purpose. The treatment of cancer-induced anemia with erythropoietin-stimulating agents (ESAs) is reviewed. Summary. Before the introduction of ESAs, the only treatment option for cancer-related ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results